- Home
- PNI vs CPIX Comparison
PNI vs CPIX Comparison
Compare PNI & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- CPIX
- Stock Information
- Founded
- PNI 2002
- CPIX 1999
- Country
- PNI United States
- CPIX United States
- Employees
- PNI N/A
- CPIX N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- CPIX Health Care
- Exchange
- PNI Nasdaq
- CPIX Nasdaq
- Market Cap
- PNI 82.7M
- CPIX 68.7M
- IPO Year
- PNI N/A
- CPIX 2009
- Fundamental
- Price
- PNI $7.08
- CPIX $4.22
- Analyst Decision
- PNI
- CPIX
- Analyst Count
- PNI 0
- CPIX 0
- Target Price
- PNI N/A
- CPIX N/A
- AVG Volume (30 Days)
- PNI 26.4K
- CPIX 131.8K
- Earning Date
- PNI 01-01-0001
- CPIX 03-04-2025
- Dividend Yield
- PNI 4.76%
- CPIX N/A
- EPS Growth
- PNI N/A
- CPIX N/A
- EPS
- PNI N/A
- CPIX N/A
- Revenue
- PNI N/A
- CPIX $37,867,945.00
- Revenue This Year
- PNI N/A
- CPIX N/A
- Revenue Next Year
- PNI N/A
- CPIX N/A
- P/E Ratio
- PNI N/A
- CPIX N/A
- Revenue Growth
- PNI N/A
- CPIX N/A
- 52 Week Low
- PNI $6.03
- CPIX $1.04
- 52 Week High
- PNI $7.89
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- PNI 33.65
- CPIX 43.04
- Support Level
- PNI $7.07
- CPIX $3.91
- Resistance Level
- PNI $7.35
- CPIX $4.47
- Average True Range (ATR)
- PNI 0.08
- CPIX 0.36
- MACD
- PNI -0.02
- CPIX -0.17
- Stochastic Oscillator
- PNI 9.37
- CPIX 23.37
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.